본문 바로가기

추천 검색어

실시간 인기 검색어

학술논문

Cannabidiol Treatment for Lennox-Gastaut Syndrome at a Single Tertiary Center in South Korea

이용수 0

영문명
Cannabidiol Treatment for Lennox-Gastaut Syndrome at a Single Tertiary Center in South Korea
발행기관
대한소아신경학회
저자명
Han Na Jang Min-Jee Kim Mi-Sun Yum Tae-Sung Ko
간행물 정보
『Annals of Child Neurology(구 대한소아신경학회지)』vol.31 no.1, 20~26쪽, 전체 7쪽
주제분류
의약학 > 소아과학
파일형태
PDF
발행일자
2022.12.30
4,000

구매일시로부터 72시간 이내에 다운로드 가능합니다.
이 학술논문 정보는 (주)교보문고와 각 발행기관 사이에 저작물 이용 계약이 체결된 것으로, 교보문고를 통해 제공되고 있습니다.

1:1 문의
논문 표지

국문 초록

영문 초록

Purpose: This study evaluated the efficacy and tolerability of cannabidiol (CBD) as an add-on therapy for childhood-onset Lennox-Gastaut syndrome (LGS). Methods: This retrospective study enrolled patients who visited the Department of Pediatric Neurology at Asan Medical Center from March 2019 to February 2022 and were treated with CBD. Electronic medical records and clinically relevant factors (including the type of epilepsy and seizures, etiology, and the number of concomitantly used anti-epileptic drugs) were reviewed. The outcome was clinical response to CBD (≥50% or <50% seizure reduction at 1, 3, and 6 months after CBD introduction and the last follow-up visit). Relevant adverse events were monitored. Results: Thirty patients were included. The median age of epilepsy onset was 5.5 years (interquartile range [IQR], 3.3 to 25.3), with a median treatment duration of CBD of 6 months (IQR, 3.3 to 7.0). Sixteen patients (53.3%) showed ≥50% seizure reduction at the last follow-up. In a univariate analysis, patients whose epilepsy commenced after 3 years of age were more likely to respond to CBD (odds ratio, 10.11; 95% confidence interval, 1.05 to 97.00; P=0.04). Adverse events were observed in 11 patients (36.6%); the most common adverse event was somnolence. Conclusion: CBD could be a treatment option for children and young adults with drug-resistant LGS with a tolerable safety profile. Age at epilepsy onset (>3 years) was associated with a favorable response to CBD treatment. Further prospective studies with larger populations are needed to evaluate the tolerability and efficacy of CBD in patients with drug-resistant epilepsy of various etiologies.

목차

Introduction
Materials and Methods
Results
Discussion
References

키워드

해당간행물 수록 논문

참고문헌

교보eBook 첫 방문을 환영 합니다!

신규가입 혜택 지급이 완료 되었습니다.

바로 사용 가능한 교보e캐시 1,000원 (유효기간 7일)
지금 바로 교보eBook의 다양한 콘텐츠를 이용해 보세요!

교보e캐시 1,000원
TOP
인용하기
APA

Han Na Jang,Min-Jee Kim,Mi-Sun Yum,Tae-Sung Ko. (2022).Cannabidiol Treatment for Lennox-Gastaut Syndrome at a Single Tertiary Center in South Korea. Annals of Child Neurology(구 대한소아신경학회지), 31 (1), 20-26

MLA

Han Na Jang,Min-Jee Kim,Mi-Sun Yum,Tae-Sung Ko. "Cannabidiol Treatment for Lennox-Gastaut Syndrome at a Single Tertiary Center in South Korea." Annals of Child Neurology(구 대한소아신경학회지), 31.1(2022): 20-26

결제완료
e캐시 원 결제 계속 하시겠습니까?
교보 e캐시 간편 결제